TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05268094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ductal Arterial Stent
Description: Drug-eluting ductal arterial stents will be placed by transcatheter method.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic-to-Pulmonary Artery Shunt
Description: A surgical connection will be made between a systemic artery and the pulmonary artery.
Study: NCT06741072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine
Description: Given OSU-2131 SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QS21
Description: Given SC
Study: NCT06739408

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lean red meat
Description: 30g of protein from lean beef.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: Whey protein to provide 30g protein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin (Placebo)
Description: Maltodextrin, to provide 0g protein but matched isocalorically
Study: NCT06740266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships in Primary Care (PFR-PC)
Description: Promoting First Relationships® in Primary Care is based on attachment theory and is strengths-based. The intervention is delivered in 10 home visits, with 2 additional clinic visits. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting.
Study: NCT06734884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 MG/ML [Fasenra]
Description: Subcutaneous injection 30 mg at day 2, week 4 and week 8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride
Description: Subcutaneous injection at day 2, week 4 and week 8
Study: NCT06743295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEEPSONIC™ Deep Sound Optimized Neural Integrated Chip Artificial intelligence-based noise reduction
Description: Participants with hearing loss will be fitted with the Phonak Audéo Sphere™ Infinio (PAI) hearing aid with artificial intelligence (AI)-based noise reduction, which incorporates deep neural networks (DNN) technology to reduce background noise.~Speech stimuli, presented at a comfortable level of approximately 60 dB SPL (like normal conversation), will be delivered via a loudspeaker positioned directly in front of the participant.~They will be tested in 3 listening environments: quiet, moderate noise, high noise.~Speech perception scores will be measured as a function of each hearing aid program setting: quiet setting, moderate noise, and advanced AI-based reduction for high noise.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEEPSONIC™ Deep Sound Optimized Neural Integrated Chip Artificial intelligence-based noise reduction
Description: Participants with hearing loss will be fitted with the Phonak Audéo Sphere™ Infinio (PAI) hearing aid with artificial intelligence (AI)-based noise reduction, which incorporates deep neural networks (DNN) technology to reduce background noise.~Speech stimuli, presented at a comfortable level of approximately 60 dB SPL (like normal conversation), will be delivered via a loudspeaker positioned directly in front of the participant.~They will be tested in 3 listening environments: quiet, moderate noise, high noise.~Speech perception scores will be measured as a function of each hearing aid program setting: quiet setting, moderate noise, and advanced AI-based reduction for high noise.
Study: NCT06738823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: INTERVENTION GROUP : TRAINING WITH WIIFIT
Description: RCT (RANDOMIZED CONTROL TRIAL) GROUP 1 : Wii FIT TRAINING TIGHT ROPE TENSION, SKI SLALOM, PENGUIN SLIDE, TABLE TILT GROUP 2 : VESTIBULAR REHABILITATION TRAINING WEIGHT SHIFTING, NECK ROTATIONS, SIT TO STAND EXERCISES ON PADDED MAT AND HEAD MOVEMENTS WITH EYES CLOSED.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VESTIBULAR REHABILITATION TRAINING
Description: WEIGHT SHIFTING, NECK ROTATIONS, SIT TO STAND EXERCISES ON PADDED MAT AND HEAD MOVEMENTS WITH EYES CLOSED.
Study: NCT06739421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nCLE-NB-rEBUS-forcep biopsy
Description: The participants would undergo lung biopsy using forcep, under the guidance of bronchoscopic needle-based confocal laser endomicroscopy (nCLE) with the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nCLE-NB-rEBUS-TBCB
Description: The participants would undergo transbronchial crybiopsy (TBCB), under the guidance of bronchoscopic needle-based confocal laser endomicroscopy (nCLE) with the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NB-rEBUS-forcep biopsy
Description: The participants would undergo lung biopsy using forcep, under the guidance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NB-rEBUS-TBCB
Description: The participants would undergo transbronchial crybiopsy (TBCB), under the guidance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
Study: NCT06739902

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Traditional Physiotherapy Group
Description: Participants receive standard physiotherapy exercises aimed at improving motor function, balance, and trunk stability. These exercises include stretching, balance training, and muscle-strengthening activities.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VR + Traditional Physiotherapy Group
Description: Participants receive the same physiotherapy exercises as the traditional group, but with additional sessions involving virtual reality exercises. The VR component includes immersive activities that stimulate motor control, coordination, and cognitive engagement to support functional recovery.
Study: NCT06747546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: goal-directed treatment strategy based on oxygen supply and consumption balance
Description: The oxygen extraction rate immediately after CPB is set as E1, the oxygen extraction rate at 4 hours after surgery is E2, and the oxygen extraction rate at 8 hours after surgery is E3. A goal-directed treatment strategy based on oxygen supply and consumption balance is defined as: Combined with the value of E2 at 4 hours after CPB, the increasing oxygen consumption (VO2) after CPB is compensated by increasing oxygen delivery (DO2) to different degrees. The goal of E3 not increasing significantly compared with E1 is achieved at 8 hours after CPB, and the severity of low cardiac output is finally reduced within the golden 8 hours after CPB.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment group
Description: Ventilation support is adjusted to maintain arterial oxygen partial pressure and oxygen saturation. Appropriate fluid infusion to stabilize central venous pressure and ensure preload; Combined use of vasoactive drugs to maintain heart rate and blood pressure; Appropriate diuresis can improve urine output and reduce cardiac afterload. Blood transfusion is used to improve coagulation function and maintain appropriate hematocrit.
Study: NCT06740825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Single oral dose of 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Single oral dose of 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rufinamide
Description: Twice daily (BID) dose of 400 mg on Days 1 through 32
Study: NCT06747897

Intervention type: DEVICE
Intervention: MINERAL OIL + PETROLATUM (DIPROBASE® Advanced Eczema Cream, BAY987534, UI 1613882)
Description: Product experience is assessed based on the answers provided by participants on the questions provided to them using an online questionnaire.

Intervention type: DEVICE
Intervention: MINERAL OIL + PETROLATUM (DIPROBASE® Advanced Eczema Cream, BAY987534, UI 1613882)
Description: Product experience is assessed based on the answers provided by participants on the questions provided to them using an online questionnaire.

Intervention type: DEVICE
Intervention: MINERAL OIL + PETROLATUM (DIPROBASE® Advanced Eczema Cream, BAY987534, UI 1613882)
Description: Product experience is assessed based on the answers provided by participants on the questions provided to them using an online questionnaire.
Study: NCT06747533

Intervention type: OTHER
Intervention: Standard Patient Education
Description: If participants are found to be eligible to take part in this study, participants will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups: the Standard Patient Education group or the Breathe Radiation Protocol Coaching group. This is done because no one knows if one study group is better, the same, or worse than the other group.~If participants are in the Standard Participants Education group, participants will receive standard of care participants education.

Intervention type: OTHER
Intervention: Breathe Radiation Protocol Coaching group
Description: If participants are in the Breathe Radiation Protocol Coaching group, participants will have access to a video that helps guide participants through a relaxed breath hold for the radiation treatment and also access to a coach for questions about the breathing process during radiation. This coaching will take place in the week before participants undergo radiation planning.
Study: NCT06741969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Description: Protocol-defined topical and systemic standard of care background treatments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care treatment
Description: Protocol-defined topical and systemic standard of care background treatments.
Study: NCT06750471

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Dupilumab is an anti-IL 4-13 biologic therapy that has been recently approved for use in recurrent chronic rhinosinusitis with nasal polyposis.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab is an anti-IL 4-13 biologic therapy that has been recently approved for use in recurrent chronic rhinosinusitis with nasal polyposis.
Study: NCT06737939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intravenous ibuprofen
Description: A systemic analgesic (NSAID) administered intravenously for pain management during prostate biopsy, without the need for additional invasive interventions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: periprostatic nerve block
Description: A local anesthetic injection targeting the periprostatic nerves to provide direct pain relief during the biopsy procedure, considered the gold standard for pain management in prostate biopsies.
Study: NCT06758739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin (Turmeric)
Description: Curcumin Capsule will be given two per day for three months. Patient Recovery progress will be monitored month on month basis for consecutive three month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Steroid Injection
Description: Intralesional Steroid Injection (1cc), one per week, will be administered in the fibrous bands wherever formed in the oral cavity. Patient recovery progress will be monitored on monthly basis for three months.
Study: NCT06774144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezafungin
Description: Rezafungin 400 mg IV once within 24 hours of liver transplant, followed by 200 mg IV weekly for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care antifungal prophylaxis
Description: UPMC uses a tiered approach to antifungal prophylaxis, based on risk factors for IFI. Fluconazole is used for recipients with risk factors for yeast infections: choledochojejunostomy, prolonged transplant time, receipt of \>40 units of blood products within 24 hours of transplant, and Candida colonization or infection within 3 months prior to transplant. Voriconazole is used for recipients with risk factors for mould infections: re-transplantation, renal failure requiring renal replacement therapy, fulminant hepatic failure as indication for transplant, intra-abdominal/thoracic re-exploration within the first month after transplant. No prophylaxis is given if there are no risk factors for yeast or mould infections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care antifungal prophylaxis
Description: UPMC uses a tiered approach to antifungal prophylaxis, based on risk factors for IFI. Fluconazole is used for recipients with risk factors for yeast infections: choledochojejunostomy, prolonged transplant time, receipt of \>40 units of blood products within 24 hours of transplant, and Candida colonization or infection within 3 months prior to transplant. Voriconazole is used for recipients with risk factors for mould infections: re-transplantation, renal failure requiring renal replacement therapy, fulminant hepatic failure as indication for transplant, intra-abdominal/thoracic re-exploration within the first month after transplant. No prophylaxis is given if there are no risk factors for yeast or mould infections.
Study: NCT06772974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxylamine Succinate USP
Description: Tab. Doxylamine Succinate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Ginger (zingiber officinale)
Study: NCT06773234

Intervention type: OTHER
Intervention: Questionnaire
Description: DREEM Tool
Study: NCT06772792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: Oral administration
Study: NCT06770660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: A 10-week telemedicine-based exercise programme consisting of 90-minute sessions conducted weekly via a video conferencing platform.~All participants will also be educated on physical activity recommendations, including achieving a minimum of 12,000 steps daily, and required to perform weekly check-in for number of daily steps via online survey form.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle
Description: All participants will be educated on physical activity recommendations, including achieving a minimum of 12,000 steps daily, and required to perform weekly check-in for number of daily steps via online survey form.
Study: NCT06771427

Intervention type: OTHER
Intervention: acupuncture GB20 or GB20 plus BL2
Description: acupuncture at acupoint GB20 or GB20 plus BL2 twice a week 8 weeks for efficacy evaluation.

Intervention type: OTHER
Intervention: acupuncture GB20 or GB20 plus BL2
Description: acupuncture at acupoint GB20 or GB20 plus BL2 twice a week 8 weeks for efficacy evaluation.

Intervention type: OTHER
Intervention: acupuncture GB20 or GB20 plus BL2
Description: acupuncture at acupoint GB20 or GB20 plus BL2 twice a week 8 weeks for efficacy evaluation.

Intervention type: DRUG
Intervention: Chinese herbal tea TBDESJS
Description: Chinese herbal tea TBDESJS 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation.

Intervention type: DRUG
Intervention: Chinese herbal tea TBDESJS
Description: Chinese herbal tea TBDESJS 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation.

Intervention type: DRUG
Intervention: Chinese herbal tea TBDESJS
Description: Chinese herbal tea TBDESJS 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation.

Intervention type: DRUG
Intervention: Chinese herbal tea TBDESJS
Description: Chinese herbal tea TBDESJS 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation.
Study: NCT06779630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System
Description: Orsiro Mission is composed of a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
Study: NCT06779149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment for Insomnia (CBT-I)
Description: Participants in this treatment group will receive CBT-I. CBT-I sessions will occur weekly for the first 4 sessions and biweekly for the last 2 sessions (treatment phase is thus 8 weeks). : Graduate level students in clinical psychology will serve as therapists for this project.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: Participants assigned to this group will be prescribed 5 to 10 mg of lemborexant to be taken at bedtime in 5 mg capsules. Lemborexant (Dayvigo) is a Dual Orexin Receptor Antagonist approved by Health Canada for the treatment of adult with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Pharmacy staff will package medications for each participant in a generic bottle labeled with the participant's ID code and treatment dates (identical for the lemborexant and placebo arms). Six consultation visits will be conducted during the 8-week treatment phase to monitor treatment response and drug side effects. The starting dose will be 5 mg with titration to 10 mg if needed (i.e., based on clinical response and tolerability) following the first week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants assigned to this group will be prescribed 5 to 10 mg of placebo to be taken at bedtime in 5 mg capsules identical to lemborexant. Pharmacy staff will package medications for each participant in a generic bottle labeled with the participant's ID code and treatment dates (identical for the lemborexant and placebo arms). Six consultation visits will be conducted during the 8-week treatment phase to monitor treatment response and drug side effects. The starting dose will be 5 mg with titration to 10 mg if needed (i.e., based on clinical response and tolerability) following the first week.
Study: NCT06778447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIA Disc NP
Description: VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.
Study: NCT06779539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Ensartinib 225 mg oral once daily 12 weeks
Study: NCT06773026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate
Description: Open-label design with doses of sodium phenylbutyrate at 4.0 g/m2/day
Study: NCT04982614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil ® 9
Description: GARDASIL 9 is a vaccine indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer, and Genital warts (condyloma acuminata) caused by Human Papillomavirus (HPV).~0.5-mL suspension for intramuscular injection as a single-dose vial and prefilled syringe at the following regimen/schedule: 9 through 14 years - 2-dose at 0, 6 to 12 months OR 3-dose at 0, 2, 6 months 15 through 45 years - 3-dose at 0, 2, 6 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil ® 9
Description: GARDASIL 9 is a vaccine indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer, and Genital warts (condyloma acuminata) caused by Human Papillomavirus (HPV).~0.5-mL suspension for intramuscular injection as a single-dose vial and prefilled syringe at the following regimen/schedule: 9 through 14 years - 2-dose at 0, 6 to 12 months OR 3-dose at 0, 2, 6 months 15 through 45 years - 3-dose at 0, 2, 6 months
Study: NCT06083623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM001
Description: single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose intramuscular injection
Study: NCT04967170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Platelet-Rich Plasma (PRP)
Description: Two intralesional injections of approximately 5-6mL given approximately 6 weeks apart

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Intralesional needle insertion without any injectate.
Study: NCT04872777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Healthy Weight
Description: Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention:~1. Noom application set-up and troubleshooting on smartphone (license provided)~2. Digital scale provision (subjects may keep the scale)~3. Capture of available clinical information over preceding 28-days.
Study: NCT06524882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivid Vision
Description: dichoptic video games played through a virtual reality headset

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminopia
Description: dichoptic movies/shows shown through a virtual reality headset

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Correction
Description: Glasses prescribed at investigator discretion
Study: NCT05658029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARINA-1
Description: Fixed-dose solution of ascorbic acid and reduced glutathione nebulized twice daily for 4 weeks (28 days)
Study: NCT06535399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986369
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986369
Description: Specified dose on specified days
Study: NCT06781125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion
Description: JCXH-211:Tumor lesions are selected for intratumoral injection, and target or non-target lesions can be selected. The number of lesions selected for injection will be at the investigator 's discretion based on the patient' s general condition and tolerability .~Anti-PD-1 antibody:Dosage and administration according to the instructions.